Treating endometriosis with a laparoscopy will not cure adenomyosis-related heavy menstrual bleeding (HMB)

Treating endometriosis with a laparoscopy will not cure adenomyosis-related heavy menstrual bleeding (HMB).

If a woman undergoes an invasive laparoscopy, the surgeon is focused on excising or ablating endometriosis tissue outside the uterus (on the ovaries, pelvic wall, bladder, or bowel). While this can be highly effective for relieving certain types of pelvic pain and deep dyspareunia, it does absolutely nothing to fix the pathology inside the uterine muscle wall itself.

Because the laparoscopy leaves the adenomyosis completely untouched, the woman will wake up from an invasive surgery only to find that her heavy, exhausting menstrual bleeding remains exactly the same.

This clinical mismatch underscores why a distinct, targeted approach is necessary for adenomyosis:

Why Laparoscopy Fails Heavy Bleeding from Adenomyosis

• Different Locations: Endometriosis is extrauterine (outside the uterus). Adenomyosis is intrauterine (inside the thick muscle wall of the uterus).
• The Root of HMB: Adenomyosis causes severe bleeding because the misplaced endometrial tissue inside the uterine muscle prevents the uterus from contracting efficiently during a period to shut off blood vessels. A standard laparoscopy cannot access or repair this diffuse, spongy muscle tissue.

The Problem with “Surgical-Only” Mindsets

When a patient presents with both conditions (which is incredibly common), a purely surgical approach often forces a difficult choice:

1. Laparoscopy only: Fixes external endometriosis pain but fails to treat the heavy bleeding from adenomyosis.
2. Hysterectomy: Fixes both, but is highly invasive, carries a longer recovery, and completely removes the organ, which is unacceptable for women wanting to preserve their uterus or fertility.

Why Uterine Artery Embolisation (UAE) Bridges the Gap

This exact scenario is why many women turn to Interventional Radiologists for Uterine Artery Embolisation (UAE) instead of, or in conjunction with, gynaecological laparoscopic surgery.

Unlike a laparoscopy, UAE directly targets the blood supply of the uterus itself. By injecting microscopic particles into the uterine arteries, the procedure starves the hypervascular, diseased adenomyotic tissue. This causes the adenomyosis to shrink and soften, directly addressing the root cause of the heavy menstrual bleeding and structural pain without requiring a hysterectomy or major abdominal incisions.

 

The fact that a standard laparoscopy for endometriosis does not resolve adenomyosis-related heavy menstrual bleeding (HMB) is absolutely evidence-based and firmly established in gynaecological clinical guidelines.

The medical literature heavily supports this reality due to two distinct, evidence-backed factors:

1. Different Mechanisms of Bleeding

Clinical studies show that the heavy menstrual bleeding in adenomyosis is caused by structural and biochemical changes inside the uterine muscle (myometrium). The presence of adenomyotic tissue disrupts the normal, coordinated muscle contractions required to constrict spiral arterioles and stop bleeding during menstruation.

Conversely, pelvic endometriosis lesions—which a laparoscopy targets—are located entirely outside the uterine cavity (e.g., on the peritoneum, ovaries, or pouch of Douglas). Removing these external lesions has no physiological mechanism for altering how the inner uterine muscle contracts.

2. High Rates of Coexistence (The Diagnostic Trap)

Data published in journals like Human Reproduction and the American Journal of Obstetrics and Gynaecology (AJOG) show that endometriosis and adenomyosis coexist in up to 40% to 80% of women presenting with chronic pelvic pain.

Because endometriosis lesions are easily visualized and biopsied via laparoscopy, it is frequently diagnosed and treated first. However, large-scale patient outcome cohorts consistently demonstrate that when a patient undergoes an excision laparoscopy for concurrent disease, their pelvic pain may improve, but their heavy menstrual bleeding scores remain unchanged post-surgery if the underlying adenomyosis is left untreated.

What the Evidence Suggests for Clinical Practice

Because a laparoscopy cannot treat intra-myometrial disease, international clinical consensus guidelines (such as those from ESGE and AGES) recommend:

• Pre-operative Imaging: Utilizing high-resolution transvaginal ultrasound (MUSA criteria) or pelvic MRI prior to a laparoscopy to explicitly look for signs of adenomyosis (like asymmetrical uterine wall thickening or myometrial cysts).
• Targeted Intrauterine/Endovascular Therapy: If heavy menstrual bleeding is the primary symptom, treatment must target the uterus directly—either medically (hormonal suppression), surgically (if a hysterectomy is chosen), or via non-surgical Uterine Artery Embolisation (UAE), which clinical trials show effectively reduces uterine volume and dramatically controls HMB by cutting off the blood supply to those adenomyotic zones.

References

Below is the updated reference list, now including the core clinical insights and data points from each paper to show exactly how they support the reality of managing concurrent endometriosis and adenomyosis.

1. On the fact that laparoscopy leaves adenomyosis untouched:

Landi S, Pontrelli G, Surico D, Ruffini N, Minelli L, Focardi G, et al. The influence of adenomyosis in patients laparoscopically treated for endometriosis. J Minim Invasive Gynecol. 2008;15(5):566-70.

• Core Insight: This paper highlights a critical shift in pelvic pain management. It argues that while laparoscopy targets superficial or deep external inflammation (endometriosis), it completely misses the internal tissue invasion characteristic of adenomyosis. Women continue to suffer from persistent, severe symptoms like heavy menstrual bleeding (HMB) even after a technically successful laparoscopy.

2. On the high rate of coexistence between the two conditions:

Lazzeri L, Di Giovanni A, Exacoustos C, et al. Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis. Reprod Sci. 2014;21(8):1027-1033

• Core Insight: This study establishes the massive overlap between these two conditions, finding that nearly half (48.1%) of women diagnosed with deep infiltrating endometriosis (DIE) also have coexisting adenomyosis. This statistical link proves why treating only one side of the disease equation surgically often leaves patients with unresolved bleeding and pain symptoms.

3. Liang’s initial 117-patient clinical audit on UAE for adenomyosis:

Liang E, Brown B, Rachinsky I. A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. Aust N Z J Obstet Gynaecol. 2018;58(4):454-459.

• Core Insight: This audit demonstrated excellent short-to-medium-term efficacy for non-surgical uterine artery embolisation (UAE). Out of 117 women with severe symptoms, UAE achieved an overall clinical success rate of 89%, specifically controlling heavy menstrual bleeding in 88% of patients and dysmenorrhea in 90%, providing a robust, uterus-preserving alternative to major surgery.

4. Liang’s 5-year long-term follow-up study on the same cohort:

Liang E, Brown B, Kirsop R, Twigg S, Sacks R, Stuart A. Efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Long-term outcomes. Aust N Z J Obstet Gynaecol. 2021;61(1):134-141.

• Core Insight: Addressing the question of whether UAE benefits last over time, this 5-year follow-up tracked the same cohort and found that the cumulative clinical success rate remained strong at 80% at a mean of 52 months. It proved that UAE provides durable, long-term symptom relief, with only a small fraction (5%) of women eventually needing a hysterectomy.

5. The Australian national clinical guideline for managing heavy bleeding:

Australian Commission on Safety and Quality in Health Care (ACSQHC). Heavy Menstrual Bleeding Clinical Care Standard. Sydney: ACSQHC; 2020. Available from ACSQHC.

• Core Insight: This national standard mandates that care must be patient-centered, less invasive, and fully informed. It outlines that women presenting with heavy menstrual bleeding must be offered a choice of highly effective medical or minimally invasive options (including uterine artery embolisation) and clearly states that a hysterectomy should generally only be considered when other less invasive treatments have been discussed, offered, or exhausted.